Search clinical trials for: Autologous CAR-T cell therapy

Total 92517 results

Celgene
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

Multiple Myeloma

Austria, United States, Spain, Australia, Japan, France, Israel, Italy, Canada, Greece, Belgium, Norway, Romania, Czechia, Denmark, Germany, Korea, Republic of, United Kingdom, Poland
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd; Suzhou Hongci Hematology...

Recruiting

Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell | Autologous Stem Cell Transplantation

China
Hideho Okada, MD, PhD
National Cancer Institute (NCI); California Institute for Regenerative Medicine...

Recruiting

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

Glioblastoma | Recurrent Glioblastoma | EGFR Gene Mutation | MGMT-Unmethylated Glioblastoma

United States
Chimeric Therapeutics

Recruiting

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy

Gastric Cancer | Colorectal Cancer | Neuroendocrine Tumors

United States
A2 Biotherapeutics Inc.
Tempus AI

Recruiting

A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression (EVEREST-2)

Cancer | Colorectal Cancer | Ovarian Neoplasms | Ovarian Cancer | NSCLC | Lung Cancer | Rectal Cancer | Non Small Cell Lung Cancer | Mesothelioma | Mesothelioma, Malignant | Colon Cancer | Pancreas Cancer | Colorectal Adenocarcinoma | Solid Tumor, Adult | CRC | Pancreatic Neoplasm | Ovary Cancer | NSCLC, Recurrent | Non-Small Cell... and other conditions

United States
Celgene
Bristol-Myers Squibb

Recruiting

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)

Multiple Myeloma

Austria, United States, Spain, Australia, Japan, France, Korea, Republic of, Israel, Italy, Canada, Greece, Belgium, Norway, Romania, United Kingdom, Czechia, Denmark, Germany, Poland
CARsgen Therapeutics Co., Ltd.
Fudan University

Recruiting

A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer

Pancreatic Cancer

China
Joshua Sasine, MD, PhD

Recruiting

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

Multiple Myeloma | Acute Lymphoblastic Leukemia | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Hematologic Malignancy | Large B-cell Lymphoma

United States
A2 Biotherapeutics Inc.
Tempus AI

Recruiting

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression (EVEREST-1)

Cancer | Colorectal Neoplasms | Colorectal Cancer | Pancreatic Neoplasms | Pancreatic Cancer | NSCLC | Solid Tumor | Non Small Cell Lung Cancer | Colorectal Cancer Metastatic | Pancreas Cancer | Colorectal Adenocarcinoma | Solid Tumor, Adult | CRC | NSCLC, Recurrent | Non Small Cell Lung Cancer Recurrent | Non-Small Cell...

United States
Nektar Therapeutics

Recruiting

NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma

Non-Hodgkin Lymphoma | Relapsed/Refractory Diffuse Large B-cell Lymphoma

United States
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies

Lymphoma | Multiple Myeloma | Acute Lymphoblastic Leukemia

China
Oncternal Therapeutics, Inc

Recruiting

A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies

Relapsed/Refractory Aggressive B-Cell Malignancies

United States
Luminary Therapeutics
The Cleveland Clinic; Case Western Reserve University

Recruiting

LMY-920 for Treatment of Relapsed or Refractory Myeloma (LMY-920-002)

Multiple Myeloma in Relapse | Multiple Myeloma, Refractory

United States
The Affiliated People's Hospital of Ningbo University
UTC Therapeutics Inc.

Recruiting

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

Lymphoma | Leukemia | Myeloma | Relapsed/Refractory Hematological Malignancies

China
Peking University
CARsgen Therapeutics Co., Ltd.

Recruiting

Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors

Pancreatic Cancer | Gastric Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

China
University of Florida
United States Department of Defense; AM Rosen Foundation

Recruiting

Phase I Study of IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma (IMPACT) (IMPACT)

Glioblastoma | Glioblastoma Multiforme

United States
The First Affiliated Hospital of Soochow University
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Recruiting

Anti-BCMA CAR T-Cell Therapy for R/R ITP

ITP

China
Stichting European Myeloma Network
Janssen Research & Development, LLC

Recruiting

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)

Multiple Myeloma

Netherlands, United States, Spain, Belgium, France, Italy, Germany, Japan, Canada, Australia, Sweden, Israel, United Kingdom, Czechia, Greece, Switzerland, Norway
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital

Recruiting

Safety and Efficacy of CD19/CD22 Dual Targeted CAR-T Cell Therapy in R/R B-Cell Acute Lymphoblastic Leukemia

CD19+ and CD 22+ B-ALL

China
St. Jude Children's Research Hospital

Recruiting

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

Melanoma | Soft Tissue Sarcoma | Carcinoma | Osteosarcoma | Ewing Sarcoma | Rhabdoid Tumor | Neuroblastoma | Rhabdomyosarcoma | Wilms Tumor | Hepatoblastoma | Desmoplastic Small Round Cell Tumor | Pediatric Solid Tumor | Clear Cell Sarcoma | Malignant Peripheral Nerve Sheath Tumors | Adrenocortical Cancer | Germ Cell Cancer

United States
Miltenyi Biomedicine GmbH

Recruiting

DALY II USA/ MB-CART2019.1 for DLBCL

Central Nervous System Lymphoma | Transformed Lymphoma | Refractory Diffuse Large B Cell Lymphoma (DLBCL) | Primary Mediastinal B-cell Lymphoma (PMBCL) | High Grade B-cell Lymphoma (HGBCL) | Relapsed Diffuse Large B Cell Lymphoma

United States
Sabz Biomedicals
Gene Therapy Research Center, Shariati Hospital, Tehran University of Medical... and other collaborators

Not yet recruiting

CD19 Targeted CAR T Cell Therapy in Patients With Relapsed/ Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

Relapsed B Cell Acute Lymphoblastic Leukemia (ALL) | Refractory B Cell Acute Lymphoblastic Leukemia (ALL)

Iran, Islamic Republic of
Memorial Sloan Kettering Cancer Center
Atara Biotherapeutics

Recruiting

Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma

Malignant Pleural Mesothelioma (MPM)

United States
Cabaletta Bio

Recruiting

A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)

Pemphigus Vulgaris

United States
Fred Hutchinson Cancer Center
Mustang Bio

Recruiting

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic... and other conditions

United States
Center for International Blood and Marrow Transplant...

Recruiting

CIBMTR Research Database

Solid Tumors | Gene Therapy | Allogeneic Stem Cell Transplantation | Autologous Stem Cell Transplantation | Blood Cancers | Non-malignant Disease | CAR-T

United States
Juno Therapeutics, a Subsidiary of Celgene

Completed

Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma (EVOLVE)

Multiple Myeloma

United States
Sangamo Therapeutics

Active, not recruiting

Safety & Tolerability Study of Chimeric Antigen Receptor T-Reg Cell Therapy in Living Donor Renal Transplant Recipients (STEADFAST)

End Stage Renal Disease | Kidney Transplant Rejection

Belgium, Netherlands, United Kingdom
Juno Therapeutics, a Subsidiary of Celgene

Active, not recruiting

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

Follicular Lymphoma | Non-Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal B-cell Lymphoma | Mantle-cell Lymphoma

United States
Novartis Pharmaceuticals

Active, not recruiting

Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (BELINDA)

Non-Hodgkin Lymphoma

Spain, Taiwan, Australia, Belgium, Germany, Italy, Singapore, Austria, France, Switzerland, Hong Kong, United States, Netherlands, Norway, United Kingdom, Brazil, China, Japan
Calibr, a division of Scripps Research

Enrolling by invitation

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

Transformed Follicular Lymphoma | Burkitt Lymphoma | Waldenstrom Macroglobulinemia | Lymphoplasmacytic Lymphoma | Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Primary Mediastinal Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma (DLBCL) | Mantle Cell Lymphoma (MCL) | Follicular... and other conditions

United States
Calibr, a division of Scripps Research

Active, not recruiting

CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies

Transformed Follicular Lymphoma | Burkitt Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Lymphoplasmacytic Lymphoma | Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Primary Mediastinal Large B Cell Lymphoma | Follicular Lymphoma (FL) | Marginal Zone Lymphoma... and other conditions

United States
Juno Therapeutics, a Subsidiary of Celgene

Completed

Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)

Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Lymphoma, Nonhodgkin

United States
Juno Therapeutics, a Subsidiary of Celgene
Bristol-Myers Squibb

Completed

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

Neoplasms | Neoplasms by Histologic Type | Lymphoma | Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphoproliferative Disorders | Lymphatic Diseases | Immunoproliferative Disorders | Lymphoma, Non-Hodgkin | Immune System Disorder

United States
Bellicum Pharmaceuticals

Suspended

Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Solid Tumor, Adult | HER-2 Gene Amplification | HER-2 Protein Overexpression

United States
Shanghai Pudong Hospital
UTC Therapeutics Inc.

Withdrawn

Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies

Acute Myeloid Leukemia (AML) | Multiple Myeloma (MM) | B-cell Non-Hodgkin's Lymphoma (B-NHL) | T-Cell Leukemia/Lymphoma, Adult | B-cell Acute Lymphoblastic Leukemia (B-ALL)

China
Juno Therapeutics, a Subsidiary of Celgene

Terminated

Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL) (ROCKET)

Acute Lymphoblastic Leukemia

United States
Aeon Therapeutics (Shanghai) Co., Ltd.
Renmin Hospital of Wuhan University; Eureka Therapeutics Inc.

Terminated

Clinical Study of ET1402L1-CAR T Cells in AFP Expressing Hepatocellular Carcinoma

Liver Neoplasms | Hepatocellular Carcinoma | Liver Cancer | Metastatic Liver Cancer

China
Qingdao Central Hospital
Yake Biotechnology Ltd.

Unknown

CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation

Lymphoma, B-Cell | Leukemia, B-Cell | Minimal Disease, Residual

China
Rong Tao
Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

Recruiting

CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL

Acute Lymphoblastic Leukemia, in Relapse | B-cell Lymphoma Refractory | B-cell Lymphoma Recurrent | Acute Lymphoblastic Leukemia With Failed Remission

China
Instituto de Investigación Biomédica de Salamanca
Carlos III Health Institute

Recruiting

Study of the Hematopoietic Niche and the Role of Inflammation in the Pathophysiology of Cytopenias After CAR-T Cell Therapy: Potential of Therapies Directed to Repair the Bone Marrow Microenvironment

Diffuse Large B Cell Lymphoma

Spain
Shenzhen Geno-Immune Medical Institute
The No.2 Clinical Hospital of the Ministry of Health

Recruiting

Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma

Multiple Myeloma | Plasmacytoma

China, Russian Federation
Essen Biotech

Not yet recruiting

Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells (BAH246)

T Cell Lymphoma | T Cell Prolymphocytic Leukemia | T-cell Acute Lymphoblastic Leukemia | T Cell Leukemia | T-Cell Lymphoma of CNS | T Cell Childhood ALL

China
Liangjing Lu
Shanghai Ming Ju Biotechnology Co., Ltd.

Not yet recruiting

Relmacabtagene Autoleucel for the Treatment of Systemic Sclerosis

Systemic Sclerosis

China
Kite, A Gilead Company
Arcellx, Inc.

Not yet recruiting

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (iMMagine-3)

Multiple Myeloma
The Children's Hospital of Zhejiang University...
Leman Biotech Co., Ltd

Recruiting

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

Acute Lymphoblastic Leukemia | Non-hodgkin Lymphoma

China
Instituto de Investigación Biomédica de Salamanca
Spanish Clinical Research Network - SCReN; Fundación Canaria de Investigación... and other collaborators

Recruiting

Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology (TranspoCART19)

B-cell Lymphoma Recurrent | Refractory B-Cell Lymphoma

Spain
University Hospital, Toulouse
Janssen, LP; Ligue contre le cancer, France

Not yet recruiting

Real-life Management of Patients Eligible for CAR-T Cell Therapy (CARAVAGE)

Hemopathy

France
Ruijin Hospital

Not yet recruiting

CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors

B-NHL, Extranodal, TP53 Alterations, Bulky Mass
National Cancer Institute (NCI)

Not yet recruiting

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic, B-Cell | B-Cell Chronic Lymphocytic Leukemia | B-Lymphocytic Leukemia, Chronic

United States

Search clinical trials for: Autologous CAR-T cell therapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations